These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38642260)

  • 1. Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan.
    Wang CY; Zhou FL; Gandhi AB; Lee TY; Cui N; Mao JS; Chen JF
    Diabetes Ther; 2024 Jun; 15(6):1389-1401. PubMed ID: 38642260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study.
    Kosjerina V; Carstensen B; Amadid H; Vistisen D
    Diabetologia; 2023 Oct; 66(10):1908-1913. PubMed ID: 37505281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
    Bailey TS; Wu J; Zhou FL; Gupta RA; Menon AA; Berhanu P; Westerbacka J; Van Vleet J; Blonde L
    Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
    Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland.
    Thomann R; Zechmann S; Alexander-David N; Jornayvaz FR
    Diabetes Metab Syndr Obes; 2020; 13():2359-2365. PubMed ID: 32753920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
    Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Continuous Usage of a Diabetes Management App on Glycemic Control in Real-world Clinical Practice: Retrospective Analysis.
    Tu YZ; Chang YT; Chiou HY; Lai K
    J Med Internet Res; 2021 Jul; 23(7):e23227. PubMed ID: 34264192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
    Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
    Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.